Zalicus awaiting data on potential new pain medication
In addition to Z160, Zalicus is developing a T-type calcium channel blocker, Z944, for chronic or acute pain. It is also discovering Nav 1.7 channel blockers for chronic pain as part of a research collaboration with Hydra Biosciences to identify potential clinical candidates.
Mr. Renz says Z944 demonstrated efficacy in preclinical inflammatory pain models and successfully completed a Phase 1 single- and multiple-ascending dose trial in the U.K. at the end of 2012. “We also know that Z944 penetrates the brain, which is important for a potential pain drug.”
There are no approved T-type calcium channel blockers on the market, and Zacks’ Mr. Napodano describes Z944 as representing a “potentially new and revolutionary way to treat acute pain.”
The company is consulting key opinion leaders in the field for ideas about the best chance of success with the molecule, and it hopes to conduct a proof-of-concept clinical study later this year. “We’re being deliberate to find the right dosing and right indication for this potent molecule,” Mr. Renz says.